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■ KEY MESSAGES 
 
 In 2016, the Belgian, Dutch, Luxembourg and Austrian governments declared their intention to collaborate 
on pharmaceutical policy (BeNeLuxA Collaboration). KCE was asked to lead a task force responsible for 
developing a Horizon Scanning methodology for pharmaceuticals and a possible model for a joint horizon 
scanning system (HSS).  
 We propose to create a central “horizon scanning unit” to perform the joint HS activities (a newly 
established unit, an existing HS unit, or a third party commissioned and financed by the collaborating 
countries). The unit will be responsible for the identification and filtration of new and emerging 
pharmaceutical products. It will maintain and update the HS database, organise company pipeline meetings, 
and disseminate the HSS’s outputs.  
 The HS unit works closely together with the designated national HS experts in each collaborating country. 
The national HS experts will collect country-specific information, liaise between the central HS unit and 
country-specific clinical and other experts, coordinate the national prioritization process (to select products 
for early assessment), and communicate the output of the HSS to national decision makers. 
 The outputs of the joint HSS are published in the format of Lists, with links to the database entry with the 
most extensive information available at that time.  
 Access to the HS database is restricted to registered parties within the collaborating countries.  
 The establishment of an HSS requires human resources with specific skills as well as facilities and 
equipment to collect, manage, store and secure sensitive data. 
  
 KCE Report 283Cs Horizon Scanning System 3 
 
■ SYNTHESIS 
TABLE OF CONTENTS 
 
■ KEY MESSAGES .................................................................................................................................. 2 
■ SYNTHESIS .......................................................................................................................................... 3 
1. BACKGROUND, OBJECTIVES AND SCOPE ..................................................................................... 5 
2. PROPOSAL FOR A JOINT HORIZON SCANNING SYSTEM ............................................................. 5 
2.1. OBJECTIVES OF THE COLLABORATIVE HSS .................................................................................. 5 
2.2. ORGANIZATION OF A COLLABORATIVE HSS .................................................................................. 6 
2.3. SCOPE OF THE HSS ........................................................................................................................... 6 
2.4. THE HS PROCESS ............................................................................................................................... 6 
2.5. TIME HORIZON AND OUTPUTS.......................................................................................................... 7 
2.6. DATABASE CONTENT AND SOURCES ............................................................................................. 8 
2.6.1. Active scanning ....................................................................................................................... 8 
2.6.2. Main database ......................................................................................................................... 8 
2.6.3. Company pipeline meetings .................................................................................................... 9 
2.7. FILTRATION ........................................................................................................................................ 10 
2.8. PRIORITIZATION ................................................................................................................................ 10 
2.9. ESTABLISHMENT OF THE COLLABORATIVE SYSTEM ................................................................. 11 
2.9.1. Start-up investment ............................................................................................................... 11 
2.9.2. Annual cost ............................................................................................................................ 12 
2.10. SUMMARY OF THE PROPOSED JOINT HSS ................................................................................... 12 
■ RECOMMENDATIONS ....................................................................................................................... 13 
 





AHRQ  The Agency for Healthcare Research and Quality (Québec) 
EMA European Medicines Agency 
FDA Food and Drug Administration (USA) 
HS Horizon scanning  
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KCE Belgian Health Care Knowledge Centre 
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NICE The National Institute for Health and Care Excellence (UK) 
NIHR HSRIC National Institute for Health Research Horizon Scanning Research & Intelligence 
Centre, UK 
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1. BACKGROUND, OBJECTIVES AND 
SCOPE 
In 2016, the Belgian, Dutch, Luxembourg and Austrian governments 
declared their intention to collaborate on pharmaceutical policy, more 
precisely on horizon scanning (HS), health technology assessment (HTA), 
information sharing and policy exchange, and pricing and reimbursement. It 
is the goal of the collaboration to avoid duplication of efforts by dividing tasks 
and sharing data. The collaboration is currently known as the “BeNeLuxA 
Collaboration”. KCE was asked to lead a task force responsible for 
developing a HS methodology for pharmaceuticals and a possible 
model for a joint horizon scanning system (HSS).  
The scope of this study is limited to horizon scanning for 
pharmaceuticals.  
2. PROPOSAL FOR A JOINT HORIZON 
SCANNING SYSTEM 
The proposed model for a joint HSS for the BeNeLuxA collaboration was 
based on the lessons learnt from an international comparison of eight HSSs 
and the input from several stakeholders (representatives of the minister of 
health in the different countries and country experts in HS) about their needs 
and objectives with the HSS. HSSs differ in their goals, time horizon and 
customers. They make different methodological choices for the 
identification, filtration and prioritization of new or emerging products.  
2.1. Objectives of the collaborative HSS 
The joint HSS should enable the participating countries to make their local 
decisions based on the jointly collected information, as well as allow the 
collaborating countries to identify possible topics on which they could work 
together.  
The BeNeLuxA collaboration needs a HSS that serves a broad range of 
objectives relevant for different policy making processes in different 
countries:  
 to inform decision makers on emerging and new pharmaceuticals for 
reimbursement decisions and policy development; 
 to inform decision makers on issues that are relevant for the managed 
introduction and monitoring of drugs;  
 to facilitate estimation of budget impact and budget planning; 
 to allow the selection of pharmaceuticals for (international collaboration 
on) early dialogue with industry, price negotiations, HTA and registers; 
 to plan health services. 
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2.2. Organization of a collaborative HSS 
Internationally, HS is performed by diverse organizations: academic 
institutions (England), independent research institutes (US, Wales and 
Scotland), (local) health authorities (Italy and the UK), and public policy 
makers (the Netherlands, Sweden). Customers are national or regional 
health authorities (the Netherlands, Sweden and Wales), HTA agencies 
(England, the US and Italy) or health service providers or managers (the UK 
and Scotland). 
For the BeNeLuxA collaboration, we propose to create a central “HS unit” 
to perform the joint HS activities. This could be a newly established unit 
within an existing agency in one of the countries, or the expansion of the HS 
activities of an existing HS unit in one of the countries, or a third party 
commissioned and financed by the collaborating countries. 
The HS unit should be commissioned for a certain period (for example at 
least 5 years), in order to safeguard the continuity of the system and the 
expertise built up in the system.  
2.3. Scope of the HSS 
The four countries agreed on the following scope of the joint HSS: “both 
inpatient and outpatient pharmaceutical products with a potentially high 
financial, clinical and/or organizational impact on the health system”. 
The first biosimilar for a biological product, cellular therapies and/or gene 
therapies that will be licensed as medicinal products by the European 
Medicines Agency (EMA), are included in the scope. Prophylactic vaccines, 
generics and medical devices are out-of-scope for the time being.   
2.4. The HS process 
The main activities of a HSS are: 
 the identification of new and emerging pharmaceutical products that 
could enter the market within a pre-defined period of time; 
 the filtering of identified products, based on the scope and time horizon 
of the HSS; 
 the prioritization of filtered products for early assessment; 
 the early assessment of the prioritized products or groups of products 
based on available data or predictions. 
The proposed joint HS process and its outputs are graphically presented in 
Figure 1. We suggest to perform the identification as well as the filtration on 
the international level (within the collaboration), and the prioritization on the 
national level.  
The result of the joint identification process is the ‘main database’, which 
consists of all new or emerging pharmaceuticals that fall within the chosen 
time horizon for the HS. The time horizon is expressed in terms of the 
development phase of the product of interest (e.g. late phase II), rather than 
in months.  
During the filtration phase, only the products that are within the pre-defined 
scope of the HSS are selected from the main database for further follow-up. 
The filtration reduces the number of technologies on which collect in-depth 
information. In the proposal several rounds of filtration are suggested, based 
on emerging new information on the products when time moves on (see also 
section 2.7). The filtration rounds result in a set of lists, which contain 
products that are far (list 1) or less far (list 3) away from expected market 
authorization (MA).  
The prioritization phase requires an assessment of the relative urgency of 
action on each of the products in the filtered database. As this urgency may 
be country-specific, additional national information may be needed for this 
purpose. The result of the national prioritization is relevant for the selection 
of products on which to collaborate on an international level. Hence sharing 
of prioritization outcomes amongst the collaborating countries would be 
desirable.  
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Figure 1 – Proposed methodology for a joint HSS  
 
Based on an informally shared viewpoint on a possible international HS database 
from the Bureau Financial Arrangements for Pharmaceutical Products of the Dutch 
Ministry of Health, Welfare and Sport (Buro Financiële Arrangementen 
Geneesmiddelen, Ministerie van Volksgezondheid, Welzijn en Sport, Nederland). 
MA: market authorization 
                                                     
a  Conditional market authorization (MA) refers to the approval of a medicine 
that addresses unmet medical needs of patients on the basis of less 
2.5. Time horizon and outputs 
In HS there is a trade-off between early information, with more uncertainty, 
and late information with less uncertainty. The longer before MA, the higher 
the uncertainty about the products. The goal of the HSS and the context of 
the health system determine the most appropriate time horizon for the HSS.   
To accommodate for the different objectives and associated time horizons 
among the four countries, the proposed system produces three lists:  
 LIST 1: A list of products at the end of phase II OR early phase III OR 
having obtained orphan drug status OR having applied for or obtained 
fast track status through other means (e.g. conditional MAa). Drugs with 
orphan drug or fast track status will already be identified in phase I. The 
list includes a brief description of the product, such as the name of the 
molecule, the manufacturer and the target indication(s).  
 LIST 2: A list of products at the end of phase III, with an expected high 
financial, clinical or organisational impact on the health care system.  
 LIST 3: A list with expected high impact pharmaceuticals in the final 
stage of development, i.e. about 12 months before MA application; 
phase III studies are finalized. Timelines and EMA/FDA status of these 
products are followed until they either have approval or are denied 
approval.  
  
comprehensive data than normally required. The available data must indicate 
that the medicine’s benefits outweigh its risks and the applicant should be in 
a position to provide the comprehensive clinical data in the future. 
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List 1 gives the customer an idea of what is in the pipeline and can be useful 
for decision makers to identify products for which early dialogue or drug 
policy development may be desirable (early dialogue should take place 
before phase III or combined phase II/III trials in order to allow companies 
to take into account the comments made). This is particularly important for 
countries with a negative reimbursement listb, such as the UK and Austria, 
because they preferably dispose of a finalised HTA as soon as the product 
comes to the market. List 2 can be useful for national budgetary planning, 
as it encompasses products that are potentially important but not yet too 
close to MA, so that anticipation is feasible. In the US, for instance, the 
Agency for Healthcare Research and Quality (AHRQ) therefore uses a time 
horizon for the identification of new or emerging products between 24 and 
36 months before MA. List 3 allows countries to set priorities for early 
assessment and to highlight possibilities for collaborations on HTA, 
registries and/or price negotiations.  
The three lists are to be considered as the outputs of the HSS. Lists 1 and 
2 would be shared annually with the customers, while List 3 would be shared 
twice a year. The desired format of the lists can be customized: it could be 
shared as a database or a customized report could be drawn from the 
database. For example, the Dutch system produces a database with 
information on the products, including a one-sentence advice on whether a 
product should go into the price negotiation procedure or not, while the 
Swedish, US, Italian and UK systems produce early assessment reports on 
fixed time intervals (quarterly, twice a year or annually). 
In the scientific report it is extensively described which information could be 
collected for the respective lists and which sources could be used for that 
purpose. We refer the interested reader to section 5.8. 
                                                     
b  Health systems with a negative reimbursement list apply a policy of 
reimbursement by default once the product has received market authorization 
from the European Medicines Agency or the national Regulatory Authority. 
Products can be taken out of the reimbursement package, but only after a 
political appraisal process informed by HTA.   
2.6. Database content and sources 
2.6.1. Active scanning 
For the BeNeLuxA collaboration an active scanning approach is proposed, 
i.e. the HS unit actively scans information sources instead of using the 
output of another HSS. This ensures that the scanning process is in line with 
the pre-defined scope and time-horizon of the joint HSS. Sources could be 
scanned weekly or monthly. A list of sources that could be used for the 
identification of products is included in the Appendix of the scientific report.  
2.6.2. Main database 
First of all it is important that appropriate measures are taken for an optimal 
protection of the database with the information on the identified products.   
In addition, the collaboration should explore the opportunities of data 
collection automation, as a semi-automated search could significantly 
improve, accelerate and simplify the identification and data collection 
process of new pharmaceuticals. Such automated searches will, however, 
not replace input from human expertise. Input from companies and clinical 
experts may improve the filtration process (cf. infra). In this context, it should 
be investigated if and under which circumstances the pre-submission data 
gathered by EMA (and currently not accessible to non-regulatory bodies) 
can be shared with the HS unit. 
Over time, the database should evolve to a real-time database, meaning 
that every time an entry in the internal database is updated and validated by 





 KCE Report 283Cs Horizon Scanning System 9 
 
Access to the full database is restricted to the designated HS experts in 
each country (for example in Belgium this could be designated experts from 
the RIZIV – INAMI and/or the Ministry of Health). By granting access only to 
those who are paying for the system, sustainability of the joint HSS is 
enhanced, and inappropriate interpretations or expectations by lay people 
are avoided. Although the database should not be disseminated to a broader 
audience, dissemination of some findings to specific target groups (e.g. 
clinicians) in a specific user-friendly format may be considered. The format 
and frequency of such outputs depend on the output timing (i.e. how long 
before MA) and the needs of the customer. The closer to MA, the more 
information is available and hence the more in-depth the assessment can 
be. We recommend to explore the need for such assessments first and pilot 
several models (e.g. “info sheet” (1 to 2 pages, can be done within 24-48h) 
over “brief” (4-6 pages, can take 0.5 to 2 weeks) to “in-depth” (up to 40 
pages, can take 4-6 months)) before investing in their systematic production.  
2.6.3. Company pipeline meetings 
The HS unit could organize annual face-to-face company pipeline meetings 
to obtain input for the HS database, similar to the English and Swedish 
HSSs. During these meetings companies are asked to pro-actively share a 
list of upcoming products, provide information on estimated launch dates 
and estimated price ranges, and filter out products which are no longer 
relevant, e.g. because the company has discontinued the research. Other 
information, such as target population, indications or possible extension of 
indications, clinical trial results etc. collected from other sources, can also 
be verified with the companies and compared with the information provided 
to financial analysts. 
                                                     
c  Scottish Medicines Consortium. Guidance on Horizon Scanning Process. 
July 2015. Accessed on https://www.scottishmedicines.org.uk/About_SMC 
/What_we_do/Horizon_Scanning/Guidance_on_Horizon_Scanning (1st 
February 2017) 
d  For prices, alternative sources, such as investor’s websites or prices of 
comparators, should in this case be used. 
For this communication with companies to be really effective and relevant 
for the HSS, genuine commitment from companies is required. Enforcement 
may not be the best way to reach the goal of the pipeline meetings. For 
example, the UK PharmaScan is a secured central database organised and 
managed by NICE, which contains information on all products that will be 
launched in the UK. In an ideal world, all pharmaceutical companies would 
proactively fill in UK PharmaScan, but in reality companies often need 
prompting for completion of UK PharmaScan. Despite these efforts, the data 
are still considered not up-to-date and incomplete.c  
Within the scope of the present study a Belgian feasibility study was 
performed. From the six companies invited for an information exchange 
meeting on specific products in their pipeline, only three participated in a 
meeting. Yet, the companies that participated in the feasibility study 
provided useful information on, for instance, companies’ development 
priorities, product discontinuation, place in therapy, expected EMA 
submission and outcomes of unpublished trials, but were unable to provide 
country-specific pricesd.  
The Belgian Society for the Pharmaceutical Industry, Pharma.be, expressed 
its willingness to engage in a collaborative HS effort, be it under a number 
of conditions.e These conditions should be further discussed at the 
European level, more precisely it should be investigated whether the 
European Federation of Pharmaceutical Industries and Associations 
(EFPIA) and the European Biotechnology Enterprises (EBE) share the view 
of Pharma.be. 
e  First, Pharma.be wants information supplied by companies that is not publicly 
available to remain confidential (unless if contained in financial analyst 
reports). Second, they would not support the principle that participation in the 
HSS becomes a condition for reimbursement or that implicit decisions about 
reimbursement are made before a reimbursement request has been 
submitted to the Drug Reimbursement Committee. This is the case in 
England, where inclusion in the UK PharmaScan database is a pre-requisite 
for getting reimbursement. The HSS is used to select pharmaceuticals for 
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2.7. Filtration 
For the filtration process, it is recommended to use explicit criteria, based 
on the scope of the HSS. A set of possible questions which can help in this 
phase (i.e. to determine whether an identified product fits within the scope 
of the HSS and should hence be included in List 1) is presented in the 
scientific report. The filtration can be performed internally by the HS unit, or 
can involve consultation of external experts, as in the Dutch and US HSS. 
When products on List 1 are in late Phase II (or phase I for orphan drugs) or 
early Phase III, it is assessed whether they have a potential financial, 
organizational and/or clinical impact, based on the collection of additional 
(minimal) data. This is the second filtration step. For example, in order to be 
filtered into the Dutch system, products need to exceed the explicit threshold 
on one of the pre-defined cost parameters (estimated annual macro cost, 
cost per patient per year, volume risk and potential savings).  
In case of an estimated high potential impact, a product is selected for List 
2. Finally, for inclusion in List 3, the third filtration step, the explicit criteria 
used are ‘phase III finalized’ and ‘<12 months to MA request’.  
                                                     
more in-depth HTA by NICE. Third, they state that the HSS should not lead 
to a separate budget for new medicines. Fourth, they emphasize that all 
companies should get the opportunity to participate.  
2.8. Prioritization 
After filtration, products have to be prioritized for assessment. This happens 
at the national level. Each country will need to set up a systematic approach 
to use the HSS’s outputs in their policy cycle or research agenda. It can start 
based on List 2 or List 3, depending on the objective of the decision maker. 
Some products that have been selected by the central HS unit can be filtered 
out at the national level if they do not serve the national customer’s objective.  
National data collection 
Most information necessary to perform a country-specific prioritization 
process will already be included in the joint HSS’s database, but national 
prioritization may also require country-specific information (for example 
about the national incidence and prevalence, the expected proportion of 
patients eligible for the treatment, existing guidelines and current standard 
of care, costs, unmet medical and societal need, impact on current care and 
health services). Involvement of national clinical and other experts (health 
system specialists, HTA experts, hospital managers, payers, insurers and 
patient associations) in this process will be needed. This creates 
transparency and supports subsequent decisions, but also helps to obtain 
information from different perspectives. The possible downside of it is that it 
may be time consuming and comes with a cost. Our feasibility study in 
Belgium showed that it was not easy to engage clinical experts, but once 
involved, they provided useful information on the context of the novel 
treatment (e.g. current standard-of-care, the medical need in (specific) 
patient population(s) and the estimation of the volume of patients in each 
treatment line) and the products’ place in therapy (i.e. appropriate target 
patient population, first, second or third line, substitution of other product(s)). 
Expert involvement can be organized through written forms and/or group 
meetings.  
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Also the involvement of an investor should be considered in this phase. 
Some investor’s websites or commercial news sites provide data on costs 
without a reference. In that case, an investor could help in assessing the 
reputation of the website. 
Although the prioritization process itself it not a collaborative effort, it is wise 
to share the country-specific information and priorities with the central 
HS unit in order to facilitate further collaboration downstream of the HS 
process.  
Prioritization process 
Prioritization processes can be explicit, quantitative processes or 
consensus-based processes or something in between. A set of explicit 
priority setting criteria increases the transparency and consistency of the 
prioritization process.  
Impact on health care expenditures and impact on the organisation of health 
care (e.g. utilization, infrastructure, system of care delivery) are the main 
explicit prioritization criteria used in current systems. Other explicit criteria 
are health benefits, innovativeness, volume of patients and impact on 
access. Besides explicit criteria, also implicit prioritization criteria could play 
a role, such as policy priorities and advice given by medical societies or 
clinical experts. While similar prioritization criteria may be used across 
countries, the respective weights assigned to these criteria will depend on 
the context, preferences and goal of the decision makers.  
More details on the prioritization process are provided in the scientific report 
section 5.11.  
2.9. Establishment of the collaborative system 
2.9.1.  Start-up investment 
The initial investment depends on how the system is established: as a new 
HS unit or as a collaboration with an existing HS initiative with prior 
experience.  
For the establishment of a new unit, an initial investment is needed for 
training people in the HS process, methodology and communication skills. 
In case a new HS unit is established in one of the collaborating countries, it 
is important to ensure that this unit closely connects to the relevant decision-
making agencies in the other collaborating countries. Therefore, a HS 
representative should be appointed in each of these agencies. 
Resources are needed for the development of the database and the web-
based interface. As explained before, functionalities to make the process as 
efficient as possible should be explored, but also data security should be 
guaranteed. It can take up to 6 months to create an initial database, while it 
should take less time in case of collaboration with an existing initiative. 
Alternatively, an initial database can be acquired from AHRQ, NIHR HSRIC 
or UKmi or the Ludwig Boltzmann Institute (oncology products only), but 
then still additional development will be needed to customize the database 
to the BeNeLuxA Collaboration’s needs.  
Contacts need to be made with pharmaceutical companies and medical 
societies at the country level to explain their role in the process and set up 
productive relationships. This effort should not be underestimated: it is time 
consuming but important to obtain the right information. 
A pilot phase is proposed to test the proposed HSS with its different outputs, 
data sources and stakeholder input procedures, and to develop practical 
output formats. The pilot phase is estimated to take about 1.5 year (or at 
least two “List 2” cycles). During this pilot phase it can be evaluated whether 
the involvement of a financial analyst is an added value in the validation of 
the (cost) data or in the development of new methodologies for cost and 
budget estimations. 
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2.9.2. Annual cost 
The annual cost of the HSS will depend on the extent of the HS activities. 
For a complete system, covering all types of health technology and not just 
pharmaceuticals, it is estimated that up to 10 full-time equivalents with 
diverse competences would be needed. A system with a limited scope, such 
as the one described in the current proposal, could do with less. The HS unit 
requires services from  
 a medical librarian 
 HS analysts with HTA and/or health economics expertise or with 
background in pharmacoeconomics 
 a pharmacologist 
 a HS analyst with medical background (medical doctor) 
 a data manager 
 a communication specialist (for the production of “high impact reports”) 
 an ICT specialist 
 a manager or coordinator 
Also for the subscription to sources, rent and facilities an annual budget will 
be needed. Outsourcing to a for-profit third party might require a premium 
above the costs. 
2.10. Summary of the proposed joint HSS 
The features of the proposed HSS are presented in Figure 2. 
Figure 2 – Features of the proposed joint HSS 
Identification International collaboration Yes No 
Active scanning  Yes No 
Company input Yes No 
Expert input Yes No 
Filtration International collaboration Yes No 
Criteria Explicit Implicit 
Company input Yes No 
Stakeholder input Yes No 
Dissemination Early assessment Yes No 
Public availability Yes No 
The proposal suggests to collaborate on the identification and filtration. A 
central HS unit could perform the HS tasks for the collaboration, including 
the maintenance and update the HS database, the organization of the 
company pipeline meetings and the support of national HS experts. The 
outputs of the joint HSS are three lists, with links to the database entry with 
the most extensive information available at that time. Access to the database 
is restricted to registered parties within the collaborating countries.  
The current proposal describes a quite extensive system, which is to be 
envisaged in the long term. However, for the short term, suggestions are 
made on how to start with an operational HSS that serves quite some needs 
of the collaboration. If, in the longer term, more countries wish to step in or 
use the HSS’s outputs, the scope can be enlarged. For maximal relevance, 
the described HS process should be adopted in a flexible way, taking the 
specific needs of the customers into account. Therefore, continuous 
communication with the collaborating countries is of utmost importance as 
well as regular evaluation of the HSS.  
 




To the BeNeLuxA collaboration 
 Set up a central horizon scanning unit to perform the horizon scanning activities for the 
collaboration. This could be a newly established unit within an existing agency in one of 
the countries, the expansion of the HS activities of an existing HS unit in one of the 
countries or a third party. 
 Provide resources to support the activities of the horizon scanning unit. 
 Pilot test the methodology proposed. 
 Develop an evaluation framework for the joint horizon scanning system. 
 Perform an evaluation of the horizon scanning system and make adjustments where 
needed. 
To the national governments 
 Support the integration of horizon scanning in your national health policy processes. 
 Appoint a national horizon scanning expert, that is the single point of contact in the 
country for all matters relating to horizon scanning. The national horizon scanning expert 
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